Arbutus Biopharma Corp (ABUS) — Cash Flow-to-Debt Ratio
Arbutus Biopharma Corp (ABUS) has a Cash Flow-to-Debt Ratio of -0.26x as of December 2025, meaning its operating cash flow of $-4.68 Million could theoretically repay 0% of its total liabilities ($18.04 Million) in one year. See Arbutus Biopharma Corp free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arbutus Biopharma Corp Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Arbutus Biopharma Corp across 28 annual periods. Also explore ABUS year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Arbutus Biopharma Corp (1998–2025)
Year-by-year debt coverage analysis for Arbutus Biopharma Corp. For market capitalisation and broader financial context, see market value of Arbutus Biopharma Corp.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.20x | $-39.64 Million | $18.04 Million | ▼ -16.3% |
| 2024 | -1.89x | $-64.85 Million | $34.34 Million | ▲ +15.7% |
| 2023 | -2.24x | $-85.94 Million | $38.38 Million | ▼ -270.9% |
| 2022 | -0.60x | $-35.36 Million | $58.57 Million | ▲ +68.7% |
| 2021 | -1.93x | $-67.53 Million | $35.05 Million | ▼ -31.5% |
| 2020 | -1.46x | $-51.44 Million | $35.11 Million | ▲ +32.3% |
| 2019 | -2.17x | $-71.01 Million | $32.79 Million | ▲ +11.8% |
| 2018 | -2.45x | $-67.90 Million | $27.67 Million | ▼ -176.2% |
| 2017 | -0.89x | $-48.60 Million | $54.70 Million | ▼ -11.9% |
| 2016 | -0.79x | $-57.88 Million | $72.90 Million | ▼ -138.6% |
| 2015 | -0.33x | $-54.78 Million | $164.61 Million | ▲ +19.1% |
| 2014 | -0.41x | $-12.42 Million | $30.20 Million | ▲ +23.6% |
| 2013 | -0.54x | $-6.74 Million | $12.52 Million | ▼ -118.9% |
| 2012 | 2.85x | $33.27 Million | $11.68 Million | ▲ +421.9% |
| 2011 | -0.89x | $-7.52 Million | $8.50 Million | ▲ +19.0% |
| 2010 | -1.09x | $-11.25 Million | $10.29 Million | ▼ -35.8% |
| 2009 | -0.80x | $-5.24 Million | $6.51 Million | ▲ +61.6% |
| 2008 | -2.09x | $-8.48 Million | $4.05 Million | ▼ -397.5% |
| 2007 | -0.42x | $-2.72 Million | $6.46 Million | ▲ +5.7% |
| 2006 | -0.45x | $-2.62 Million | $5.88 Million | ▼ -13.2% |
| 2005 | -0.39x | $-14.57 Million | $36.99 Million | ▼ -103.6% |
| 2004 | -0.19x | $-9.98 Million | $51.60 Million | ▲ +94.7% |
| 2003 | -3.67x | $-26.96 Million | $7.35 Million | ▼ -59.0% |
| 2002 | -2.31x | $-18.16 Million | $7.87 Million | ▼ -41.1% |
| 2001 | -1.64x | $-10.00 Million | $6.12 Million | ▲ +51.2% |
| 2000 | -3.35x | $-8.35 Million | $2.49 Million | ▲ +5.9% |
| 1999 | -3.56x | $-6.84 Million | $1.92 Million | ▲ +35.1% |
| 1998 | -5.49x | $-7.71 Million | $1.40 Million | — |